These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 23011321)
1. The acute effect of fludrocortisone on basal and hCRH-stimulated hypothalamic--pituitary--adrenal (HPA) axis in humans. Karamouzis I; Berardelli R; Marinazzo E; D'Angelo V; Zinnà D; Minetto MA; Zichi C; Fussotto B; Giordano R; Ghigo E; Arvat E Pituitary; 2013 Sep; 16(3):378-85. PubMed ID: 23011321 [TBL] [Abstract][Full Text] [Related]
2. The acute effect of a mineralocorticoid receptor agonist on corticotrope secretion in Addison's disease. Berardelli R; Karamouzis I; D'Angelo V; Fussotto B; Minetto MA; Ghigo E; Giordano R; Arvat E J Endocrinol Invest; 2016 May; 39(5):537-42. PubMed ID: 26450146 [TBL] [Abstract][Full Text] [Related]
3. Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans. Berardelli R; Karamouzis I; Marinazzo E; Prats E; Picu A; Giordano R; Ghigo E; Arvat E Eur J Endocrinol; 2010 Jun; 162(6):1067-74. PubMed ID: 20219855 [TBL] [Abstract][Full Text] [Related]
4. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Buckley TM; Mullen BC; Schatzberg AF Psychoneuroendocrinology; 2007; 32(8-10):859-64. PubMed ID: 17666187 [TBL] [Abstract][Full Text] [Related]
5. The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Otte C; Jahn H; Yassouridis A; Arlt J; Stober N; Maass P; Wiedemann K; Kellner M Life Sci; 2003 Aug; 73(14):1835-45. PubMed ID: 12888122 [TBL] [Abstract][Full Text] [Related]
6. Overnight suppression of HPA axis after mineraolocorticoid receptor stimulation: A sleep endocrine study. Demiralay C; Agorastos A; Jahn H; Kellner M; Yassouridis A; Wiedemann K Psychiatry Res; 2015 May; 227(1):65-70. PubMed ID: 25799272 [TBL] [Abstract][Full Text] [Related]
7. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. Grottoli S; Maccagno B; Ramunni J; Di Vito L; Giordano R; Gianotti L; DeStefanis S; Camanni F; Ghigo E; Arvat E J Endocrinol Invest; 2002 May; 25(5):420-5. PubMed ID: 12035937 [TBL] [Abstract][Full Text] [Related]
8. Free fatty acids exert an inhibitory effect on adrenocorticotropin and cortisol secretion in humans. Lanfranco F; Giordano R; Pellegrino M; Gianotti L; Ramunni J; Picu A; Baldi M; Ghigo E; Arvat E J Clin Endocrinol Metab; 2004 Mar; 89(3):1385-90. PubMed ID: 15001638 [TBL] [Abstract][Full Text] [Related]
9. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Lembke A; Gomez R; Tenakoon L; Keller J; Cohen G; Williams GH; Kraemer FB; Schatzberg AF Psychoneuroendocrinology; 2013 Jan; 38(1):115-21. PubMed ID: 22727477 [TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. Otte C; Yassouridis A; Jahn H; Maass P; Stober N; Wiedemann K; Kellner M J Gerontol A Biol Sci Med Sci; 2003 Oct; 58(10):B900-5. PubMed ID: 14570856 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of hypothalamo-pituitary-adrenocortical function in children by human corticotropin-releasing hormone (MCI-028) test. Tanaka T; Hibi I; Shimizu N; Imura H; Tanaka K; Fukata J; Fujieda K; Ichimura T; Kuribayashi T; Ito K Endocr J; 1993 Oct; 40(5):581-9. PubMed ID: 7951524 [TBL] [Abstract][Full Text] [Related]
12. The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease. Avgerinos PC; Nieman LK; Oldfield EH; Loughlin T; Barnes KM; Loriaux DL; Cutler GB J Clin Endocrinol Metab; 1989 May; 68(5):912-6. PubMed ID: 2541160 [TBL] [Abstract][Full Text] [Related]
13. Primary hyperaldosteronism is associated with derangement in the regulation of the hypothalamus-pituitary-adrenal axis in humans. Giordano R; Pellegrino M; Picu A; Bonelli L; Oleandri SE; Pellissetto C; Limone P; Migliaretti G; Maccario M; Ghigo E; Arvat E J Endocrinol Invest; 2007; 30(7):558-63. PubMed ID: 17848838 [TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. Arvat E; Maccagno B; Giordano R; Pellegrino M; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E J Clin Endocrinol Metab; 2001 Jul; 86(7):3176-81. PubMed ID: 11443185 [TBL] [Abstract][Full Text] [Related]
15. A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus-pituitary-adrenal axis more integrally in healthy volunteers. Jacobs GE; van Gerven JM; de Kam Ml; Elassaiss-Schaap J; Ruigt G; van Pelt J; Peeters BW; Peeters PA; Hulskotte EG J Psychopharmacol; 2011 Mar; 25(3):361-9. PubMed ID: 20147570 [TBL] [Abstract][Full Text] [Related]
16. Recovery from glucocorticoid inhibition of the responses to corticotrophin-releasing hormone. Watson AC; Rosenfield RL; Fang VS Clin Endocrinol (Oxf); 1988 May; 28(5):471-7. PubMed ID: 2850875 [TBL] [Abstract][Full Text] [Related]
17. The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro. Calogero AE; Scaccianoce S; Burrello N; Nicolai R; Muscolo LA; Kling MA; Angelucci L; D'Agata R J Neuroendocrinol; 1996 Aug; 8(8):579-85. PubMed ID: 8866244 [TBL] [Abstract][Full Text] [Related]
18. Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralocorticoid receptor blockade. Giordano R; Bo M; Pellegrino M; Vezzari M; Baldi M; Picu A; Balbo M; Bonelli L; Migliaretti G; Ghigo E; Arvat E J Clin Endocrinol Metab; 2005 Oct; 90(10):5656-62. PubMed ID: 16014406 [TBL] [Abstract][Full Text] [Related]
19. Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans. Dorin RI; Ferries LM; Roberts B; Qualls CR; Veldhuis JD; Lisansky EJ J Clin Endocrinol Metab; 1996 Nov; 81(11):3883-91. PubMed ID: 8923833 [TBL] [Abstract][Full Text] [Related]
20. Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans. Arvat E; Maccagno B; Ramunni J; Maccario M; Giordano R; Broglio F; Camanni F; Ghigo E Eur J Endocrinol; 2000 Jul; 143(1):99-104. PubMed ID: 10870037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]